TScan Therapeutics, Inc. layoffs
Yes. TScan Therapeutics, Inc. has filed 2 SEC 8-Ks with Item 2.05 (exit or disposal costs) since 2023. The most recent, on Sep 2, 2026, disclosed a workforce reduction.
Check TCRX layoff riskSEC filings since 2023
- Sep 22026
TScan Therapeutics discloses a workforce reduction
TScan Therapeutics, Inc. (TCRX) · filed 10 weeks agoOn September 2, 2026, TScan Therapeutics, Inc. (the "Company") initiated a prioritization strategy by which the Company will prioritize the preclinical development of its in vivo solid tumor program and pause further enrollment in its Phase 3 ALLOHA-2 TM study of TSC-101.
- Nov 32025
TScan Therapeutics to cut about 66 jobs (30% of workforce)
TScan Therapeutics, Inc. (TCRX) · filed 53 weeks agoOn November 3, 2025, TScan Therapeutics, Inc. (the "Company") initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity.
Get this data via API
Pull layoff filings, risk scores, and WARN notices into your own product. Starts at $49/mo.